LUC00064I2 - - Google Patents

Download PDF

Info

Publication number
LUC00064I2
LUC00064I2 LU00064C LUC00064C LUC00064I2 LU C00064 I2 LUC00064 I2 LU C00064I2 LU 00064 C LU00064 C LU 00064C LU C00064 C LUC00064 C LU C00064C LU C00064 I2 LUC00064 I2 LU C00064I2
Authority
LU
Luxembourg
Application number
LU00064C
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00064(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of LUC00064I1 publication Critical patent/LUC00064I1/fr
Publication of LUC00064I2 publication Critical patent/LUC00064I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
LU00064C 2004-12-22 2018-02-12 LUC00064I2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
EP05823474A EP1827461B1 (fr) 2004-12-22 2005-12-20 Régime posologique de cladribine pour le traitement de la sclérose en plaques
EP14001970.4A EP2805723B1 (fr) 2004-12-22 2005-12-20 Régime posologique de cladribine pour le traitement de la sclérose en plaques
EP10182676.6A EP2263678B1 (fr) 2004-12-22 2005-12-20 Régime posologique de cladribine pour le traitement de la sclérose en plaques précoce sécondaire progressive

Publications (2)

Publication Number Publication Date
LUC00064I1 LUC00064I1 (fr) 2018-02-14
LUC00064I2 true LUC00064I2 (fr) 2018-03-28

Family

ID=36227798

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00064C LUC00064I2 (fr) 2004-12-22 2018-02-12

Country Status (25)

Country Link
US (2) US7713947B2 (fr)
EP (7) EP2275110B1 (fr)
JP (7) JP5795456B2 (fr)
KR (1) KR20070091662A (fr)
AR (1) AR052830A1 (fr)
AU (2) AU2005318190B2 (fr)
BR (1) BRPI0517132B8 (fr)
CA (2) CA2588966C (fr)
CY (3) CY1112614T1 (fr)
DK (3) DK3332789T3 (fr)
EA (1) EA015799B1 (fr)
ES (2) ES2921858T3 (fr)
FI (1) FI4070800T3 (fr)
FR (1) FR18C1008I2 (fr)
HR (1) HRP20120228T1 (fr)
HU (3) HUE059133T2 (fr)
IL (2) IL183930A0 (fr)
LT (3) LT3332789T (fr)
LU (1) LUC00064I2 (fr)
MX (1) MX2007007610A (fr)
NO (1) NO20073813L (fr)
PL (4) PL2805723T3 (fr)
SG (1) SG160391A1 (fr)
SI (3) SI2805723T1 (fr)
WO (1) WO2006067141A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2805723T3 (pl) 2004-12-22 2018-04-30 Merck Serono Sa Schemat dawkowania kladrybiny dla leczenia stwardnienia rozsianego
MX2008014971A (es) * 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
EP2343074A1 (fr) 2009-12-23 2011-07-13 Merck Serono S.A. Utilisation d'analogues de la purine pour traiter des maladies des voies respiratoires
WO2011117267A1 (fr) 2010-03-24 2011-09-29 Merck Serono Sa Traitement à la cladribine de la sclérose en plaques chez des groupes de patients définis par génotype
EP2428201A1 (fr) 2010-09-08 2012-03-14 Merck Serono S.A. Administration orale de nucléosides monophosphates
WO2012097867A1 (fr) 2011-01-18 2012-07-26 Synthon Bv Particules de cladribine et compositions pharmaceutiques comprenant celles-ci
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
AR113906A1 (es) * 2017-11-24 2020-06-24 Merck Patent Ges Mit Beschraenkter Haftung Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
IL301246A (en) 2020-09-10 2023-05-01 Merck Patent Gmbh Treatment regimen with cladribine
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (fr) 1984-08-06 1990-05-29 Brigham Young University Preparation de composes a base de 2'-desoxyadenosine
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
PL321431A1 (en) 1994-12-22 1997-12-08 Ortho Pharma Corp Soluble 2-chloro-2'deoxyadenosine compositions
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (fr) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. Procede de production de 2-chloro-2'-desoxyadenosine (cladribine) et son derive 3,5-di-o-p-toluoyle
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
WO2004028462A2 (fr) 2002-09-25 2004-04-08 Brigham Young University, Technology Transfer Office Procede de preparation de composes de 2-halo-2'-deoxyadenosine a partir de 2'-deoxyguanosine
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
BRPI0407781A (pt) * 2003-02-25 2006-02-14 Applied Research Systems aplicação combinada de ribavirina e interferon beta em doenças desmielinizantes
WO2004087101A2 (fr) 2003-03-28 2004-10-14 Ivax Corporation Formulations de cladribine a administration par voie orale
ES2584183T3 (es) 2003-03-28 2016-09-26 Ares Trading S.A. Formulaciones de cladribina para suministro mejorado oral y transmucosa
PL2805723T3 (pl) 2004-12-22 2018-04-30 Merck Serono Sa Schemat dawkowania kladrybiny dla leczenia stwardnienia rozsianego
MX2008014971A (es) * 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.

Also Published As

Publication number Publication date
CA2588966A1 (fr) 2006-06-29
EP2263678A2 (fr) 2010-12-22
CA3087419C (fr) 2023-03-07
CA3087419A1 (fr) 2006-06-29
EP3332789A1 (fr) 2018-06-13
EP4523753A2 (fr) 2025-03-19
EP2805723A1 (fr) 2014-11-26
ES3007339T3 (en) 2025-03-19
SI2805723T1 (en) 2018-02-28
LTPA2018503I1 (lt) 2018-03-12
LT4070800T (lt) 2025-01-10
JP2018165271A (ja) 2018-10-25
EP3332789B1 (fr) 2022-04-06
AR052830A1 (es) 2007-04-04
BRPI0517132B1 (pt) 2020-02-18
KR20070091662A (ko) 2007-09-11
DK2805723T3 (da) 2018-01-29
AU2005318190B2 (en) 2010-11-25
EP1827461A1 (fr) 2007-09-05
EP4523753A3 (fr) 2025-05-28
MX2007007610A (es) 2007-08-03
EP4070800A1 (fr) 2022-10-12
JP2008524313A (ja) 2008-07-10
JP2020193206A (ja) 2020-12-03
EP1827461B1 (fr) 2012-02-29
HUE070333T2 (hu) 2025-05-28
JP6430554B2 (ja) 2018-11-28
HUE059133T2 (hu) 2022-10-28
PL3332789T3 (pl) 2022-08-22
EA015799B1 (ru) 2011-12-30
JP2013216664A (ja) 2013-10-24
EP4070800B1 (fr) 2024-10-16
JP6290962B2 (ja) 2018-03-07
AU2005318190A1 (en) 2006-06-29
BRPI0517132B8 (pt) 2021-05-25
SG160391A1 (en) 2010-04-29
PL2805723T3 (pl) 2018-04-30
FR18C1008I1 (fr) 2018-03-30
LT3332789T (lt) 2022-07-25
US20090081163A1 (en) 2009-03-26
JP2017101061A (ja) 2017-06-08
LTC2805723I2 (lt) 2022-04-25
FR18C1008I2 (fr) 2019-03-01
CY2018006I1 (el) 2018-06-27
HUS1800009I1 (hu) 2018-05-02
EP2263678B1 (fr) 2014-06-11
NO20073813L (no) 2007-09-21
JP2015180685A (ja) 2015-10-15
CY2018006I2 (el) 2018-06-27
WO2006067141A1 (fr) 2006-06-29
EP2275110A3 (fr) 2011-04-27
IL212421A (en) 2014-01-30
EA200701221A1 (ru) 2008-02-28
FI4070800T3 (fi) 2025-01-14
CY1119790T1 (el) 2018-06-27
JP6092945B2 (ja) 2017-03-08
CY1112614T1 (el) 2016-02-10
AU2011200768B2 (en) 2012-09-13
JP2016138128A (ja) 2016-08-04
SI4070800T1 (sl) 2025-03-31
US7713947B2 (en) 2010-05-11
IL183930A0 (en) 2007-10-31
US20100203017A1 (en) 2010-08-12
PL4070800T3 (pl) 2025-03-10
PL1827461T3 (pl) 2012-07-31
ES2921858T3 (es) 2022-09-01
US8377903B2 (en) 2013-02-19
BRPI0517132A (pt) 2008-09-30
HRP20120228T1 (hr) 2012-04-30
EP2805723B1 (fr) 2018-01-17
EP2275110B1 (fr) 2013-07-10
JP5795456B2 (ja) 2015-10-14
IL212421A0 (en) 2011-06-30
JP5908863B2 (ja) 2016-04-26
SI3332789T1 (sl) 2022-08-31
LUC00064I1 (fr) 2018-02-14
AU2011200768A1 (en) 2011-03-17
EP2263678A3 (fr) 2011-04-27
EP2275110A2 (fr) 2011-01-19
CA2588966C (fr) 2020-07-21
DK3332789T3 (da) 2022-07-11
DK4070800T3 (da) 2025-01-02

Similar Documents

Publication Publication Date Title
FR14C0013I1 (fr)
JP2005226847A5 (fr)
IN2007DE03488A (fr)
JP2005267512A5 (fr)
JP2005270017A5 (fr)
JP2005156566A5 (fr)
IN2007DE00479A (fr)
JP2005293697A5 (fr)
JP2005267865A5 (fr)
FR18C1008I1 (fr)
JP2005146837A5 (fr)
DE602005026315D1 (fr)
JP2005223745A5 (fr)
JP2005228446A5 (fr)
JP2005157382A5 (fr)
JP2005039798A5 (fr)
JP2005090744A5 (fr)
JP2005229178A5 (fr)
JP2005222294A5 (fr)
JP2005046608A5 (fr)
IN2006KO02923A (fr)
JP2004298622A5 (fr)
JP2004305746A5 (fr)
JP2005254883A5 (fr)
JP2005023510A5 (fr)